Zeria Pharmaceutical (4559) · RiskRestated
Bad debt risk on trade receivables
First written in FY2017. 1 of 2 entries say "Restated". Latest entry: FY2019.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Risk of Divergence in Allowance-for-Doubtful-Accounts Estimates and Additional ProvisioningA theme 19 companies write about · 18 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2019: 1 of 9 companies on the "Worse" side.
10 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2019RestatedAnnual report
「If the risk of non-collection increases due to deterioration in customers’ financial condition or other factors, additional provisions may be required.」
The company continues to disclose the risk of non-collection of trade receivables and the possibility of additional provisions. - FY2017First statedAnnual report
「If the risk of non-collection increases due to deterioration in customers’ financial condition or other factors, additional provisions may be required.」
The company describes the risk of recording additional allowance for doubtful accounts due to deterioration in customers’ financial condition and other factors.